Dr. Hua Zhu (David) Ke is Founder and CEO of Angitia Biopharmaceuticals, a clinical-stage biotechnology company developing breakthrough therapeutics for serious musculoskeletal diseases. He has dedicated nearly 30 years to the discovery and development of innovative drugs for bone and musculoskeletal conditions.

Before founding Angitia in 2018, David served as Vice President and Head of Bone Therapeutic Area at UCB Pharma in the United Kingdom and Scientific Executive Director and Head of Bone Research at Amgen Inc. He helped lead the development of romosozumab (Evenity), approved by the FDA in 2019 for osteoporosis treatment.

David holds adjunct professorships at University of Utah, Chinese University of Hong Kong, and Guangdong Medical University. He was elected Fellow of the American Society for Bone and Mineral Research and serves on the Board of Directors for the International Society of Bone Morphometry.

Angitia has raised over $330 million total, including a $120 million Series C in December 2024 led by Bain Capital Life Sciences. The company has operations in Woodland Hills, California and Guangzhou, China with 83 employees advancing three clinical-stage biologics.

Angitia has achieved FDA clearance for IND applications and NMPA approval for Phase 3 trials, with drug candidates AGA111, AGA2115, and AGA2118 targeting osteoporosis, osteogenesis imperfecta, and spinal fusion. The company's bispecific antibodies represent next-generation treatments that increase bone formation while decreasing bone resorption.